NASDAQ:PPBT Purple Biotech (PPBT) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free PPBT Stock Alerts $0.49 -0.03 (-5.77%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.48▼$0.5450-Day Range$0.40▼$0.9252-Week Range$0.30▼$2.08Volume176,664 shsAverage Volume221,850 shsMarket Capitalization$12.37 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Purple Biotech alerts: Email Address Purple Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,736.7% Upside$9.00 Price TargetShort InterestHealthy0.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector717th out of 914 stocksBiotechnology Industry10th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingPurple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePurple Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.93% of the outstanding shares of Purple Biotech have been sold short.Short Interest Ratio / Days to CoverPurple Biotech has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Purple Biotech has recently increased by 5.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPurple Biotech does not currently pay a dividend.Dividend GrowthPurple Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PPBT. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Purple Biotech this week, compared to 0 articles on an average week.Search Interest6 people have searched for PPBT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Purple Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Purple Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.98% of the stock of Purple Biotech is held by insiders.Percentage Held by InstitutionsOnly 9.64% of the stock of Purple Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Purple Biotech are expected to remain at ($0.46) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Purple Biotech is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Purple Biotech is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPurple Biotech has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Purple Biotech Stock (NASDAQ:PPBT)Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Read More PPBT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PPBT Stock News HeadlinesApril 25, 2024 | globenewswire.comPurple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingApril 24, 2024 | americanbankingnews.comPurple Biotech (NASDAQ:PPBT) Trading Up 8.1%April 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 17, 2024 | investing.comPurple Biotech Ltd (PPBT)March 28, 2024 | finance.yahoo.comPurple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024March 14, 2024 | finanznachrichten.dePurple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyMarch 14, 2024 | globenewswire.comPurple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyMarch 5, 2024 | investorplace.comPPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023April 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 5, 2024 | finanznachrichten.dePurple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comPurple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 3, 2024 | investing.comPurple Biotech ADR (PPBT) Earnings Dates & ReportsFebruary 27, 2024 | markets.businessinsider.comBuy Rating Justified by Promising Phase 1 Results of Purple Biotech’s NT219 in SCCHN TreatmentFebruary 27, 2024 | morningstar.comPurple Biotech Ltd ADRFebruary 27, 2024 | globenewswire.comPurple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024February 22, 2024 | wsj.comPurple Biotech Ltd. ADRFebruary 15, 2024 | morningstar.comPurple Biotech Ltd ADR PPBTFebruary 13, 2024 | finance.yahoo.comPurple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 TrialFebruary 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)February 1, 2024 | msn.comPurple Biotech stock climbs 9% on Phase 2 study updateFebruary 1, 2024 | finance.yahoo.comPurple Biotech Reaches Recommended Phase 2 Dose for NT219December 20, 2023 | finance.yahoo.comPurple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsDecember 14, 2023 | finanznachrichten.dePurple Biotech Ltd.: Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialDecember 14, 2023 | finance.yahoo.comPurple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialNovember 22, 2023 | markets.businessinsider.comPromising Clinical Trial Results and Accelerated Enrollment Boost Purple Biotech’s Buy RatingNovember 21, 2023 | finance.yahoo.comPurple Biotech Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comPurple Biotech Fortifies NT219 Patent ProtectionSee More Headlines Receive PPBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/27/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PPBT CUSIPN/A CIK1614744 Webwww.kitovpharma.com Phone(723) 933-3121Fax972-153-39333121Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,736.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.40% Return on Assets-49.02% Debt Debt-to-Equity RatioN/A Current Ratio2.20 Quick Ratio2.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book0.36Miscellaneous Outstanding Shares25,240,000Free Float24,486,000Market Cap$12.37 million OptionableOptionable Beta0.94 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Gil Efron CPA (Age 58)M.A., Chief Executive Officer Comp: $455.44kDr. Michael Schickler Ph.D. (Age 66)Head of Clinical & Regulatory Affairs Comp: $264.98kMr. Lior Fhima CPA (Age 47)M.B.A., Chief Financial Officer Mr. Ido Morpurgo B.Sc. (Age 52)L.L.M., Vice President of Operations Key CompetitorsImunonNASDAQ:IMNNRedHill BiopharmaNASDAQ:RDHLAgeX TherapeuticsNYSE:AGEMIRA PharmaceuticalsNASDAQ:MIRATonix PharmaceuticalsNASDAQ:TNXPView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 1,882,173 shares on 2/13/2024Ownership: 8.544%WuXi AppTec Co. Ltd.Bought 194,139 shares on 2/6/2024Ownership: 0.881%View All Institutional Transactions PPBT Stock Analysis - Frequently Asked Questions Should I buy or sell Purple Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Purple Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PPBT shares. View PPBT analyst ratings or view top-rated stocks. What is Purple Biotech's stock price target for 2024? 3 equities research analysts have issued 1-year price objectives for Purple Biotech's stock. Their PPBT share price targets range from $8.00 to $10.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 1,736.7% from the stock's current price. View analysts price targets for PPBT or view top-rated stocks among Wall Street analysts. How have PPBT shares performed in 2024? Purple Biotech's stock was trading at $0.78 at the beginning of the year. Since then, PPBT shares have decreased by 37.2% and is now trading at $0.49. View the best growth stocks for 2024 here. When is Purple Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our PPBT earnings forecast. How were Purple Biotech's earnings last quarter? Purple Biotech Ltd (NASDAQ:PPBT) posted its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.15. How do I buy shares of Purple Biotech? Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PPBT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
